Significance of the RING domain of the BRCA1 gene - Review of Missense Mutations
DOI:
https://doi.org/10.58445/rars.2991Keywords:
BRCA 1, BARD 1, RING Domain, E3 ligase, missense mutationsAbstract
Breast cancer occurs around the world, and 2022 data reveal 2,308,897 new breast cancer cases accounted for 11.6% of all new cancer cases (Bray et al., 2024). Breast cancer susceptibility gene 1 (BRCA1) is one of the most common tumor suppressor genes and is detected in at least 5% of patients with breast cancer (Morris et al., 2006). BRCA1 gene mutations are prevalent and found in 35% of the hereditary breast cancer cases. Out of the three domains of the BRCA1 gene, the mutations in the RING domain near the N terminus are reviewed here. Out of the 27 mutations indicated in the RING domain, 14 missense mutations identified with a pathogenic outcome were selected for this review (Gracia et al., 2024). A missense mutation replaces the nucleotide in the gene that affects the protein folding when that gene is expressed, affecting the protein function. The BRCA1 protein forms a heterodimer with the BARD1 protein to perform E3 ligase activity. The RING region of BRCA1 is crucial for heterodimer formation. Suppose a mutation were to occur in the RING region, it might interfere with the two proteins binding to form a heterodimer, thus affecting E3 ligase activity that is crucial for gene regulation through the ubiquitination process. Missense mutations have been shown to have a pathogenic outcome and are therefore studied in detail.
References
Abkevich, V., Zharkikh, A., Deffenbaugh, A. M., Frank, D., Chen, Y., Shattuck, D., Skolnick, M. H., Gutin, A., & Tavtigian, S. V. (2004). Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. Journal of Medical Genetics, 41(7), 492–507. https://doi.org/10.1136/jmg.2003.015867
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. https://doi.org/https://doi.org/10.3322/caac.21834
Brzovic, P. S. ;, Rajagopal, P. ;, Hoyt, D. W. ;, King, M.-C. ;, & Klevit, R. E. (2001). Full wwPDB NMR Structure Validation Report i ○ Title : Solution structure of the BRCA1/BARD1 RING-domain heterodimer. https://doi.org/10.1038/nsb1001-833
Gorodetska, I., Kozeretska, I., & Dubrovska, A. (2019). BRCA genes: The role in genome stability, cancer stemness and therapy resistance. In Journal of Cancer (Vol. 10, Issue 9, pp. 2109–2127). Ivyspring International Publisher. https://doi.org/10.7150/jca.30410
Gracia, B., Montes, P., Gutierrez, A. M., Arun, B., & Karras, G. I. (2024). Protein-folding chaperones predict structure-function relationships and cancer risk in BRCA1 mutation carriers. Cell Reports, 43(2). https://doi.org/10.1016/j.celrep.2024.113803
Iii, F., Le Trong, D. ;, Stenkamp, I. ;, & Klevit, R. E. ; (2023). Full wwPDB X-ray Structure Validation Report i ○ Title : Crystal Structure of the BRCA1 Associated Ring Domain (BARD1) Tandem BRCT Domains. https://doi.org/10.2210/pdb3FA2/pdb
Machackova, E., Damborsky, J., Valik, D., & Foretova, L. (2001). Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic. Human Mutation, 18(6), 545. https://doi.org/10.1002/HUMU.1232
Morris, J. R., Pangon, L., Boutell, C., Katagiri, T., Keep, N. H., & Solomon, E. (2006). Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Human Molecular Genetics, 15(4), 599–606. https://doi.org/10.1093/hmg/ddi476
Ruffner, H., Joazeiro, C. A. P., Hemmati, D., Hunter, T., & Verma, I. M. (2001). Cancer-predisposing mutations within the RING domain of BRCA1: Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. https://doi.org/10.1073/pnas.081068398
Yang, Q., Zhao, J., Chen, D., & Wang, Y. (2021). E3 ubiquitin ligases: styles, structures and functions. In Molecular Biomedicine (Vol. 2, Issue 1). Springer. https://doi.org/10.1186/s43556-021-00043-2
Yang, Y., Swaminathan, S., Martin, B. K., & Sharan, S. K. (2003). Aberrant splicing induced by missense mutations in BRCA1: clues from a humanized mouse model. Human Molecular Genetics, 12(17), 2121–2131. https://doi.org/10.1093/hmg/ddg222
Zhang, Z., Li, T., Li, Y., Wang, X., Liu, H., Shen, X., Xu, A., Xia, T., & Xu, B. (2025). Cancer stem cell specificity as new targets in breast tumor treatment. In Oncology Research (Vol. 33, Issue 4, pp. 811–819). Tech Science Press. https://doi.org/10.32604/or.2024.050505
Downloads
Posted
Categories
License
Copyright (c) 2025 Esha Desai, Lalita Limaye

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.